NCT07182903Completed
Fatigue in MS: From Invisible to Measurable
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
Fatigue is one of the most common and burdensome symptoms of MS, but its precise cause remains unknown, and an effective treatment is lacking. Previous research has shown that the progression of MS is associated with a higher presence of a specific type of T-cell, the cytotoxic CD4+ T-cells, which play a role in the immune system. The aim of this study is to investigate whether these cells can also be linked to fatigue in people with MS.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 34 (actual)
- First submitted
- 3 Sept 2025
- Start date
- 27 Oct 2025
- Primary completion date
- 2 Apr 2026
- Lead sponsor
- University Medical Center Groningen
- Diseases
- Multiple sclerosis
- NCT number
- NCT07182903
What you commit to
- Study type: Observational
- Participants enrolled: 34
- From 27 Oct 2025 to the primary completion date, 2 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Dimethyl fumarate, fingolimod or alemtuzumab treatment, since these medications have a strong influence on the immune system As a result of these treatments, there are few to no immune cells circulating in the blood, meaning we cannot find our population of interest in the blood.
- Change in medication 6 weeks before the start of the study (including medication not related to MS) - MS relapse within 6 weeks of the start of the study
- Had an infection in the last month - Received a vaccination in the last 14 days - Pregnant or pregnancy in the last 6 months
Other illness
- Having a psychiatric disorder
- Having a neurological disorder other than MS
Other
- Having cognitive or communicative problems that makes it hard to follow instructions
Who the study is looking for
- Diagnosis of relapsing remittion, primary progressive or secondary progressive MS
- Age: 18-60 years
- Ability to perform the foot-tapping task
- Ability to walk at least 20 meters (with or without walking aid)
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UMCG Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.